Want to see JP:2931 full AI Analyst Report?
Top Page
euglena Co., Ltd.
(2931)
Select Model
Select Model
Rating:48Neutral
Price Target:
¥332.00
▼(-18.43% Downside)
Action:Reiterated
Date:08/07/26
The score is primarily held up by improving fundamentals—strong revenue growth, stable high gross margins, and much better operating and free-cash-flow performance in 2024–2025. Offsetting this are still-negative net profits/ROE and a weak technical picture (below key moving averages with negative MACD and low RSI), while valuation is constrained by losses (negative P/E) and a modest dividend yield.
Positive Factors
Revenue growth & operating turnaround
Revenue expanded substantially (roughly ¥13.3B in 2020 to ~¥50.4B in 2025) while operating profit turned positive in 2024 and improved further in 2025. Sustained top-line scale and an operating-profit turnaround indicate durable demand, improved operating leverage, and greater ability to self-fund growth and absorb shocks over the medium term.
Negative Factors
Net losses and negative ROE
Despite an operating turnaround, the company still reports net losses and negative return on equity across the period. Persistent bottom‑line deficits constrain retained earnings and shareholder returns, may necessitate future capital raises if not resolved, and limit the company's long‑term financial resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth & operating turnaround
Revenue expanded substantially (roughly ¥13.3B in 2020 to ~¥50.4B in 2025) while operating profit turned positive in 2024 and improved further in 2025. Sustained top-line scale and an operating-profit turnaround indicate durable demand, improved operating leverage, and greater ability to self-fund growth and absorb shocks over the medium term.
Read all positive factors
euglena Co., Ltd. (2931) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥50.08B
Dividend YieldN/A
Average Volume (3M)958.05K
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue Growth7.84%
EPS Growth81.48%
CountryJP
Employees793
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)-1.28
Shares Outstanding139,521,760
10 Day Avg. Volume1,429,850
30 Day Avg. Volume958,053
Financial Highlights & Ratios
PEG Ratio-3.10
Price to Book (P/B)1.76
Price to Sales (P/S)1.08
P/FCF Ratio10.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.8
Revenue Forecast (FY)¥51.90B
euglena Co., Ltd. Business Overview & Revenue Model
Company Description
Euglena Co., Ltd. is a Japanese enterprise specializing in the research, development, cultivation, and marketing of microalgae. Its operations are structured around two primary divisions: Healthcare Business and Energy/Environment Business. The co...
How the Company Makes Money
null...
euglena Co., Ltd. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
50
Neutral
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 52.32B | 50.37B | 47.62B | 46.48B | 44.39B | 27.54B |
| Gross Profit | 35.78B | 32.06B | 30.00B | 29.81B | 29.05B | 16.22B |
| EBITDA | 6.67B | 6.47B | 3.90B | 1.51B | -359.00M | -3.50B |
| Net Income | -172.00M | -805.00M | -650.00M | -2.65B | -2.67B | -4.03B |
Balance Sheet | ||||||
| Total Assets | 69.27B | 72.33B | 73.26B | 59.62B | 57.27B | 61.01B |
| Cash, Cash Equivalents and Short-Term Investments | 17.17B | 21.16B | 20.63B | 15.79B | 9.95B | 10.19B |
| Total Debt | 23.06B | 27.68B | 25.92B | 25.07B | 22.22B | 24.91B |
| Total Liabilities | 37.70B | 43.80B | 41.14B | 39.40B | 37.92B | 40.42B |
| Stockholders Equity | 33.18B | 30.96B | 31.70B | 20.21B | 19.35B | 20.58B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 4.98B | 2.23B | 345.00M | 595.00M | 1.18B |
| Operating Cash Flow | 0.00 | 5.19B | 2.65B | 658.00M | 924.00M | 1.38B |
| Investing Cash Flow | 0.00 | -585.00M | -7.99B | -646.00M | 1.23B | -10.34B |
| Financing Cash Flow | 0.00 | -2.43B | -485.00M | 5.83B | -2.99B | 12.06B |
euglena Co., Ltd. Technical Analysis
Positive
407.00
Price Trends
343.12
Positive
362.72
Negative
381.55
Negative
Market Momentum
4.05
Negative
57.62
Neutral
77.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2931, the sentiment is Positive. The current price of 407 is above the 20-day moving average (MA) of 349.70, above the 50-day MA of 343.12, and above the 200-day MA of 381.55, indicating a neutral trend. The MACD of 4.05 indicates Negative momentum. The RSI at 57.62 is Neutral, neither overbought nor oversold. The STOCH value of 77.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2931.
euglena Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ¥3.27T | 24.43 | 12.16% | 2.36% | 6.19% | 21.69% | |
69 Neutral | ¥715.51B | 21.19 | 12.11% | 1.82% | 9.67% | -2.92% | |
68 Neutral | ¥332.14B | 24.38 | 3.71% | 2.42% | 3.22% | 358.24% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | ¥421.25B | 260.17 | 1.46% | 1.87% | 3.71% | -86.23% | |
58 Neutral | ¥1.48T | -73.33 | ― | 1.64% | 4.96% | -1485.59% | |
48 Neutral | ¥50.08B | -277.34 | ― | ― | 7.84% | 81.48% |
* Consumer Defensive Sector Average
JP:2931
euglena Co., Ltd.
355.00
-98.00
-21.63%
JP:4452
Kao
3,635.00
363.16
11.10%
JP:4967
Kobayashi Pharmaceutical Co
5,690.00
468.12
8.96%
JP:4922
Kose
5,865.00
315.48
5.68%
JP:4527
Rohto Pharmaceutical Co
3,106.00
632.03
25.55%
JP:4911
Shiseido Company,Limited
3,766.00
1,408.25
59.73%
euglena Co., Ltd. Corporate Events
Euglena Turns Profitable in H1 FY2026 and Lifts Revenue Forecast on Healthcare and Biofuel Growth
Aug 7, 2026
Euglena Co., Ltd. reported robust first-half FY2026 results, with sales rising 8 percent year on year to ¥26.5 billion and operating profit up 14 percent, driven mainly by organic growth in its healthcare business. Net income turned positive ...
Euglena Returns to Profit and Lifts Full-Year Outlook on Revenue Growth
Aug 7, 2026
Euglena Co., Ltd. reported consolidated net sales of ¥26.5 billion for the six months ended June 30, 2026, an 8.0% year-on-year increase, with Adjusted EBITDA up 8.5% to ¥3.8 billion. Operating profit rose 14.3% to ¥1.9 billion, ord...
Euglena Lifts Q1 Sales on Healthcare Growth as Biofuel Rollout Advances
May 14, 2026
Euglena reported first-quarter fiscal 2026 results showing an 11% year-on-year increase in sales to ¥13.2 billion, driven mainly by 12% growth in its healthcare business and steady gains in profitability, including an 18% rise in adjusted EBI...
Euglena Boosts Profits in First Quarter and Sticks to Cash-Focused 2026 Outlook
May 14, 2026
Euglena Co., Ltd. reported consolidated net sales of ¥13.2 billion for the three months ended March 31, 2026, up 10.6% year on year, with Adjusted EBITDA rising 17.8% to ¥1.82 billion and operating profit jumping 35.4% to ¥837 milli...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.